Therapeutic cancer vaccines, J Clin Invest, vol.125, pp.3401-3412, 2015. ,
Trial watch: peptide-based anticancer vaccines, Oncoimmunology, vol.4, pp.974411-974424, 2015. ,
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J Immunol, vol.179, pp.5033-5040, 2007. ,
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, Eur J Immunol, vol.43, pp.2554-2565, 2013. ,
Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4 + T Cells, J Biol Chem, vol.284, pp.9184-9191, 2009. ,
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen, J Immunother, vol.37, pp.84-92, 2014. ,
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J Med, vol.361, pp.1838-1847, 2009. ,
An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, vol.547, pp.217-221, 2017. ,
Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine, Immunol Lett, vol.161, pp.20-30, 2014. ,
Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy, Immunol Lett, vol.163, pp.102-112, 2015. ,
Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion, Vaccine, vol.24, pp.5235-5244, 2006. ,
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides, Immunity, vol.1, pp.751-761, 1994. ,
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor, Clin Cancer Res, vol.18, pp.6284-6295, 2012. ,
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, J Exp Med, vol.205, pp.2673-2682, 2008. ,
Overexpression of meloe gene in melanomas is controlled both by specific transcription factors and hypomethylation, PLoS One, vol.8, p.75421, 2013. ,
The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences, PLoS One, vol.8, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-01726993
A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination, Cancer Immunol Immunother, vol.60, pp.327-337, 2011. ,
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients, PLoS One, vol.7, p.51716, 2012. ,
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur J Immunol, vol.40, pp.1786-1794, 2010. ,
A mouse model of human adaptive immune functions: hLA-A2.1-/HLADR1-transgenic H-2 class I-/class II-knockout mice, Eur J Immunol, vol.34, pp.3060-3069, 2004. ,
ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum, Nature, vol.419, pp.480-483, 2002. ,
Peptide length significantly influences in vitro affinity for MHC class II molecules, Immunome Res, vol.4, pp.6-7, 2008. ,
Endosomal proteases in antigen presentation, Curr Opin Immunol, vol.18, pp.78-84, 2006. ,
Twenty years of the MEROPSdatabase of proteolytic enzymes, their substrates and inhibitors, Nucleic Acids Res, vol.44, pp.343-350, 2016. ,
HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells, J Immunol, vol.188, pp.2102-2110, 2012. ,
acDCs enhance human antigen-specific T-cell responses, Blood, vol.118, pp.2128-2137, 2011. ,
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice, Oncotarget, vol.8, pp.48959-48971, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01699821
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity, Clin Cancer Res, vol.14, pp.169-177, 2008. ,